Navigation Links
GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
Date:9/11/2007

ST. JOSEPH, Mich., Sept. 11 /PRNewswire/ -- GeneGo, Inc. and the Cystic Fibrosis Foundation announced today their collaboration to develop a software suite for the integration and analysis of cystic fibrosis data. GeneGo's proprietary software combines analytical tools, data content and algorithms for understanding the complex interconnected pathways that are affected in common human diseases.

"We hope this collaboration will better help us to understand the disease and potential therapies at the molecular level," said Robert J. Beall, Ph.D., president and CEO of the Foundation. "Using computational platforms adds to our arsenal of already existing strategies."

The new platform, called MetaMiner (CF), will include off-the-shelf GeneGo products such as MetaCore, MetaDrug, MetaLink and MapEditor. Platforms such as MetaDrug can help to solve various problems including a drug's mechanism of action, toxicity and off-target effects, deduced from the structure and any kind of supplementary omics data. The product is intended to be used by medicinal chemists and biologists active in pre-clinical areas of high content and high throughput screening, bioassays, hit-to-lead. MetaMiner (CF) will include cystic fibrosis-specific OMICs and small experiments content annotated by GeneGo, disease maps and networks.

"We are very pleased to work with Cystic Fibrosis Foundation and the academic community which is very well organized and successful in research and drug discovery for the disease. We have a clear direction and end goals that we are focused on," said Julie Bryant, GeneGo's vice president of business development. "This collaboration is the first in the series of disease-centered MetaMiner projects which integrate our existing data analysis tools, OMICs data warehousing and disease-specific knowledge base. We have a dedicated group of Ph.D. and M.D. scientists to work on this project."

The project will be guided by a Cystic Fibrosis Foundation committee with a goal to leverage systems biology technology and accumulated data to advance drug discovery for this disease. MetaMiner (CF) is expected to be available by February of 2008 to cystic fibrosis academic researchers and drug development collaborators through access licenses.

Cystic fibrosis is a genetic disease that affects about 30,000 adults and children in the United States. It causes life-threatening lung infections and serious digestive complications. More than 10 million Americans are symptomless carriers of the CF gene.

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.0(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at http://www.genego.com. MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, Md., the Foundation funds CF research, has 80 chapter and branch offices throughout the country, and supports and accredits a nationwide network of 115 CF care centers, including 94 adult programs, which provide vital treatments and other CF resources to patients and families. For more information, visit http://www.cff.org.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Third Wave seeks approval of Cystic Fibrosis test
2. EraGen cystic fibrosis test to be distributed worldwide through Bayer
3. Third Wave strikes deal with Kaiser Permanente on cystic fibrosis reagents
4. Entrepreneurship grant will build strong foundation
5. UWM launches research foundation
6. NorthStar signs exclusive agreement with Illinois foundation
7. SBC Foundation awards technology grants in Wisconsin
8. SBC foundation gives Excelerator grants to local nonprofits
9. Hendee promoted to president of MCW Research Foundation; Gutterman steps up
10. Rennebohm foundation gives $15m to UW for medical research
11. Stem-cell research gets grant from M.J. Fox Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Looking for ... and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences to ... cuisine, and guests leave inspired with new cooking tips and techniques, thanks to ...
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore bio tech ... mail security screening solution at the National Postal Forum 2017 in Baltimore, Maryland, ... fast, highly accurate, easy to use and low cost threat detection solution for ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... As part ... the series will explore the laboratory testing for DIC in order to illuminate this ... disorder which can occur in hospitalized patients resulting in a high degree of morbidity ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... Physical Medicine & Rehabilitation, P.A. , proudly announced today that acclaimed physiatrist Matthew ... his duties on May 15, 2017. , Dr. Terzella completed his residency in ...
Breaking Biology Technology:
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
(Date:3/23/2017)... 23, 2017 Research and Markets has announced ... & Trends - Industry Forecast to 2025" report to their ... The ... CAGR of around 8.8% over the next decade to reach approximately ... the market estimates and forecasts for all the given segments on ...
Breaking Biology News(10 mins):